

## SELECTED TALKS / PUBLICATIONS

- Wang G, Aguado M, Spear M, Alphas L, Chen C, Huang H, Lu X, **Doostzadeh J**, Wu S, Wang S, Patel A, Nemeroff CB, Wang Z, Li A, and Luo W. ANK3, a novel genetic biomarker for lialfensine in treatment-resistant depression. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2025.2416 September 10, 2025.
- **Doostzadeh J**. Measuring the operational value of combination trials in oncology to pinpoint its use in oncology Research. Guest Speaker, Clinical Operations in Oncology Conference 2019.
- **Doostzadeh J**. Optimization recruitment rates by collaboration and analyzing data for targeted patient population. Guest Speaker, Clinical Operations in oncology conference, 2017.
- **Doostzadeh J**. Operational oversight of late phase studies on a global basis. Guest Speaker, MASS Conference 2016.
- Ronca AE, **Doostzadeh J**, Dumars PM, Carrillo NE, Smith JD. Specimen biobanking for the Human Research Program (HRP). Proceedings of the Joint meeting of the American Society for Gravitational and Space Research (ASGSR) and the International Symposium for Physical Sciences in Space (ISPS5), 2013, IP.28:136.
- Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, **Doostzadeh J**, Williams JE, Farhat N, Caputo R, Lansky AJ, Cutlip DE, Sudhir K, Stone GW. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). Am J Cardiol. 2011 Mar 15; 107(6):833-40.
- Applegate RJ, Hermiller JJ, Sanz M, **Doostzadeh J**, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GW. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention. 2010 Sep; 6(4):437-46.
- Applegate R, Hermiller J, Williams J, Gordon P, **Doostzadeh J**, Cao S, Su X, Sudhir K, Lansky A, Simonton C, Stone G. Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv. 2010 Nov 1; 76(5):644-51.
- Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, **Doostzadeh J**, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010 May 6; 362(18):1663-74.
- Onuma Y, Serruys PW, Kukreja N, Veldhof S, **Doostzadeh J**, Cao S, Stone GW; SPIRIT II and III Investigators. Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. Eur Heart J. 2010 May; 31(9):1071-8. Epub 2010 Jan 29.

- **Doostzadeh J**, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. *Coron Artery Dis.* 2010 Jan; 21(1):46-56. Review.
- Gordon PC, Applegate RJ, Hermiller JB, Weinsier SB, **Doostzadeh J**, Cao S, Sudhir K, Lansky AJ, Stone GW. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0mm registry. *Catheter Cardiovasc Interv.* 2010 Feb 1; 75(2):179-86.
- Nikolsky E, Lansky AJ, Sudhir K, **Doostzadeh J**, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GW. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. *Am Heart J.* 2009 Oct; 158(4):520-526.
- **Doostzadeh J**, Bezenek S, Cheong W-F, Sood P, Schwartz L, Sudhir K. Clinical Trials in Interventional Cardiology: Focus on the XIENCE V Drug-Eluting Stent. Book Chapter, Wiley, Clinical Trials handbook. 2009, Chapter 10.
- Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, **Doostzadeh J**, Su X, White R, Cao S, Sudhir K, Stone GW. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. *Catheter Cardiovasc Interv.* 2009 Nov 1; 74(5):719-27.
- Hermiller JB, Applegate RJ, Sanz M, Midei M, **Doostzadeh J**, Pierson W, Cao S, Sudhir K, Stone GW. Evaluation of Clinical Outcomes from Everolimus-Eluting and Paclitaxel-Eluting Stents in Elderly Patients: 2-Year Results from the SPIRIT III Randomized Trial. Abstract and Presentation at Transcatheter Cardiovascular Therapeutics, TCT 2009.
- Applegate RJ, Hermiller JB, Sanz M, **Doostzadeh J**, Pierson W, Su X, Lansky AJ, Sudhir K, Stone, JW. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients with Two Vessels Treatment: 2-year Results from the SPIRIT III Randomized Trial. Abstract and Presentation at Transcatheter Cardiovascular Therapeutics, TCT 2009.
- Lansky AJ, Applegate RJ, Hermiller JB, Cristea E, Dressler O, Koo K, **Doostzadeh J**, Su X, Simonton CA, Sudhir K, Stone GW. Side-Branch Occlusion with XIENCE V Everolimus-Eluting and TAXUS EXPRESS Paclitaxel-Eluting Stents: 2-Year Results from the SPIRIT III Randomized Trial. Award Winning abstract and presentation at Transcatheter Cardiovascular Therapeutics, TCT 2009.
- Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators, **Doostzadeh J**. is listed as member of steering committee. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. *JAMA.* 2008 Apr 23; 299(16):1903-13.
- Applegate RJ, Hermiller JB, Gordon P, Midei M, **Doostzadeh J**, Pierson W, Sood P, Su X, Cao S, Sudhir K, Stone GW. Predictors of Early and Late Clinical Outcomes in the SPIRIT III Randomized Trial of

Everolimus-eluting and Paclitaxel-eluting Stents. Abstract and Presentation at The Society for Cardiovascular Angiography and Interventions, SCAI 2009.

- Srinivasan BS, **Doostzadeh J**, Absalan F, Mohandessi S, Jalili R, Bigdeli S, Wang J, Mahadevan J, Lee CL, Davis RW, William Langston J, Ronaghi M. Whole genome survey of coding SNPs reveals a reproducible pathway determinant of Parkinson disease. *Hum Mutat.* 2009 Feb; 30(2):228-38.
- **Doostzadeh J**, Shokralla S, Absalan F, Jalili R, Mohandessi S, Langston JW, Davis RW, Ronaghi M, Gharizadeh B. High throughput automated allele frequency estimation by pyrosequencing. *PLoS One.* 2008 Jul 16; 3(7):e2693.
- **Doostzadeh J**, Tetrud JW, Allen-Auerbach M, Langston JW, Schüle B. Novel features in a patient homozygous for the L347P mutation in the PINK1 gene. *Parkinsonism Relat Disord.* 2007 Aug;13(6):359-61.
- **Doostzadeh J**, Davis RW, Giaever GN, Nislow C, Langston JW. Genomic profiling for identifying intracellular targets of toxicants producing Parkinson's disease. *Toxicol Sci.* 2007 Jan;95(1):182-7.
- **Doostzadeh-Cizeron J**, Goodrich D. The nuclear death domain protein p84N5 activates a G2/M cell cycle checkpoint prior to the onset of apoptosis. *J Biol. Chem.* 2001 Jan 12;276(2):1127-32.
- Goodrich DW, **Doostzadeh-Cizeron J**, Evans R, Poe B. Death domain protein p84N5 induces a unique apoptotic pathway from within the nucleus, in patients with prostate and breast cancer. *Cancer Detection and Prevention* 2001; 24(Supplement 1).
- **Doostzadeh-Cizeron J**, Yin S, Goodrich D. Apoptosis induced by the nuclear death domain protein p84N5 is associated with caspase-6 and NF-kB activation. *J. Biol. Chem.* 2000 Aug 18;275(33):25336-41.
- **Doostzadeh-Cizeron J**, Evans R, Goodrich D. Apoptosis induced by the nuclear death domain protein p84N5 is inhibited by association with Rb protein. *Mol. Biol. Cell.* 1999 Oct; 10 (10) 3251-61.
- **Doostzadeh J**, Cotillon AC, Benalycherif A, Morfin R. Inhibition studies of dehydroepiandrosterone 7 alpha- and 7 beta-hydroxylation in mouse liver microsomes. *Steroids.* 1998 Nov; 63(11): 608-14.
- **Doostzadeh J**, Cotillon AC, Morfin R. Hydroxylation of pregnenolone at the 7 alpha- and 7 beta-positions by human liver microsomes. Effects of cytochrome p450 inhibitors and structure-specific inhibition by steroid hormone. *Steroids.* 1998 Jul-Aug; 63(7-8): 383-92.
- **Doostzadeh J**, Cotillon AC, Morfin R. Dehydroepiandrosterone 7alpha- and 7beta-hydroxylation in brain microsomes. Effects of cytochrome P450 inhibitors and structure-specific inhibition by steroid hormones. *J. Neuroendocrinol.* 1997 Dec; 9(12): 923-8.

- Cotillon AC, **Doostzadeh J**, Morfin R. The inducible and cytochrome P450-containing dehydroepiandrosterone 7-alpha-hydroxylating enzyme system of *Fusarium moniliforme*. *J. Steroid Biochem. mol. Biol.* 1997 Aug; 62(5-6): 467-75.
- **Doostzadeh J**, Morfin R. Effects of cytochrome P450 inhibitors and of steroid hormones on the formation of 7- hydroxylated metabolites of pregnenolone in mouse brain microsomes. *J. Endocrinol.* 1997 Nov; 155(2): 343-50.
- **Doostzadeh J**, Flinois JP, Beaune P, Morfin R. Pregnenolone-7beta-hydroxylating activity of human cytochrome P450-1A1. *J. Steroid Biochem. Mol. Biol.* 1997 Jan; 60(1-2): 147-52.
- **Doostzadeh J**. Production de stéroïdes 7-hydroxylés, immunoactivateurs naturels: identification et régulation des cytochromes P450 responsables chez la souris et chez l'homme. Thèse de doctorat" (1996).
- **Doostzadeh J**, Urbun P, Pompon D, Morfin R. Pregnenolone-7 beta-hydroxylating activities of yeast-expressed mouse cytochrome P450-1A1 and mouse-tissue microsome. *Eur. J. Biochem.* 1996 Dec 15; 242(3): 641-7.
- **Doostzadeh J**, Morfin R. Study of the enzyme complex responsible for pregnenolone and dehydroepiandrosterone 7 alpha-hydroxylation in mouse tissues. *Steroids.* 1996 Oct; 61(10): 613-20.
- Tinel M, Robin MA, **Doostzadeh J**, Maratrat M, Ballet F, Fardel N, el Kahwaji J, Beaune P, Daujat M, Labbe G, et al. The interleukin-2 receptor down-regulates the expression of cytochrome P450. *Gastroenterology.* 1995 Nov; 109(5): 1589-99.
- Thal C, el Kahwaji J, Loeper J, **Doostzadeh J**, Labbe G, Leclaire J, Beaune P, Pessayre D. Administration of high doses of human recombinant interleukin-2 decreases the expression of several cytochromes P-450 (in patients with liver cancer). *J. Pharmacol Exp Ther.* 1994 Jan; 268(1): 515-21.
- **Doostzadeh J**. Effet de l'interleukine-2 sur l'expression du cytochrome P-450. Mémoire de D.E.A.(1993).